Navigation Links
Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome
Date:7/21/2014

More than 800 microRNAs have been identified in the human genome, and over one-third of all human genes are believed to be regulated by microRNAs.  A single microRNA can regulate entire networks of genes. As such, these molecules are considered master regulators of the human genome.  microRNA expression, or function, has been shown to be significantly altered or dysregulated in many disease states, including oncology, fibrosis, metabolic diseases, immune-inflammatory diseases and HCV. Targeting microRNAs with anti-miRs, chemically modified, single-stranded oligonucleotides, offers a unique approach to treating disease by modulating entire biological pathways and may become a new and major class of drugs with broad therapeutic application.

About the 'Clinical Map Initiative'

Launched in February 2014, Regulus' 'Clinical Map Initiative' outlines certain corporate goals to advance its microRNA therapeutics pipeline over the next several years. Regulus expects to demonstrate human proof-of-concept results in the Phase I clinical study of RG-101 for the treatment of HCV by the end of 2014, initiate a Phase I clinical study of RG-012 for the treatment of Alport syndrome in the first half of 2015, nominate a third microRNA candidate for clinical development by the end of 2014, and maintain a strong financial position and end 2014 with at least $75.0 million in cash, cash equivalents and short-term investments.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company.   Regulus has a well-balanced microRNA therapeutics pipeline entering clinical developm
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
2. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
3. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
4. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
5. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
6. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
7. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
8. Regulus Appoints Mark G. Foletta to its Board of Directors
9. Regulus to Present at Two Upcoming Investor Conferences
10. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
11. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. 23, ... International plc (NASDAQ: ENDP ) (TSX: ENL), ... ) announced today that they have submitted a New ... the U.S. Food and Drug Administration (FDA).  Buprenorphine HCl ... pain severe enough to require daily, around-the-clock, long-term opioid ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... Calif. , Dec. 22, 2014 Apnea ... expanded corporate offices in Aliso Viejo ... that due to the tremendous growth and worldwide expansion, ... Sales of patented SnoreRx, the anti snore cure have ... He said, "We are now in 23 countries ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... , OMAHA, Neb., Dec. 4 Amber ... Accreditation Commission for Health Care, Inc. (ACHC) for specialized ... provided comprehensive pharmacy care programs and services to meet ... one of the leading providers of services to transplant ...
... , ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE ... against biological and chemical threats, announced today the presentation of ... its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is ... up to and including 55 degrees C. The data ...
Cached Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5
(Date:12/26/2014)... “Many people become overwhelmed by the thought of ... phone calls with insurance companies,” The Jones Firm explains ... free eBook on pedestrian and bicycle accidents . ... auto accident claims assures the injured individual that a ... their case while they focus on recovering. , ...
(Date:12/26/2014)... December 26, 2014 Parker & ... the best in heating, cooling and plumbing contractor ... hour emergency services in 2014 with regard to ... that Arizona is known for its incredibly hot ... understands the intricacies and details of a wide ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... 2014 Recently, iFitDress.com, the popular online supplier ... announced its new selection of black one-shoulder cocktail dresses ... now; they are available at discounted prices, up to 70% ... will last for three weeks only. You know, we have ... are interested in our new items can visit our website ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business is ... company announces big discounts on its bamboo mats , ... is the world’s leader in bamboo flooring. According to ... 20, 2015. , The bamboo mats are made from ... All the bamboo strips for the mats are boiled ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... Randy Dotinga HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay ... nice house to a handy jet at your disposal, but the ... take years off your life? Maybe not, new research suggests. ... seem to lose years off their lives due to the effects ...
... at the meeting, which is being held in Budapest, ... using echocardiography to document early warning signs of adverse ... echocardiography to evaluate the protective role of ACE inhibitors ... "These studies open the way for the early identification ...
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) -- ... tired; it may also increase your risk of developing type 2 ... of women found that those who worked rotating night shifts were ... hours, and the longer that they worked a rotating shift schedule, ...
... are too poor to afford pacemakers. But a study has ... and implanting them in Indian patients "is very safe and ... is a co-author of the study, published online ahead of ... helped conduct the research before coming to Loyola while he ...
... Supercomputer simulations at the Department of Energy,s Oak Ridge ... key class of proteins involved in drug detoxification. ... affiliated with ORNL and the University of Tennessee, have ... in a class of enzymes called P450s. Certain types ...
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) ... hormone therapy do not appear to be at increased risk ... review of evidence. Hormone therapy called "androgen deprivation ... studies found that the therapy might increase the risk of ...
Cached Medicine News:Health News:Most U.S. Presidents Live Longer Than Their Peers 2Health News:EUROECHO 2011: Importance of echocardiography to evaluate cardio toxicity in cancer patients 2Health News:EUROECHO 2011: Importance of echocardiography to evaluate cardio toxicity in cancer patients 3Health News:EUROECHO 2011: Importance of echocardiography to evaluate cardio toxicity in cancer patients 4Health News:Rotating Shift Work May Boost Women's Diabetes Risk 2Health News:Rotating Shift Work May Boost Women's Diabetes Risk 3Health News:Reusing pacemakers from deceased patients is safe and effective, study finds 2Health News:Supercomputer reveals new details behind drug-processing protein model 2Health News:Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients 2Health News:Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: